近日，降糖减重药品GLP-1市场竞争态势升级。诺和诺德宣告全线产品大降价。恰逢节后公众降糖减重需求高峰期，“价格下探”与“需求升温”双重因素叠加，迅速在零售终端引发连锁反应。据美团买药数据显示，节后替尔泊肽、玛仕度肽、司美格鲁肽等GLP-1类药物跃居热搜榜前十。其中，司美格鲁肽搜索量较节前增长90%，替尔泊肽和玛仕度肽搜索量分别实现88%和48%的显著增长。
Source Link近日，降糖减重药品GLP-1市场竞争态势升级。诺和诺德宣告全线产品大降价。恰逢节后公众降糖减重需求高峰期，“价格下探”与“需求升温”双重因素叠加，迅速在零售终端引发连锁反应。据美团买药数据显示，节后替尔泊肽、玛仕度肽、司美格鲁肽等GLP-1类药物跃居热搜榜前十。其中，司美格鲁肽搜索量较节前增长90%，替尔泊肽和玛仕度肽搜索量分别实现88%和48%的显著增长。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.